Anest. intenziv. Med. 2025;36(1):22-28 | DOI: 10.36290/aim.2025.006

Alveolar-arterial oxygen difference in intensive careReview Article

Kutěj M.1, 2, Haiduk F.1, 2, Sagan J.3, 4, Máca J.1, 5
1 Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Ostrava a Lékařská fakulta, Ostravská univerzita, Ostrava
2 Klinika dětské anesteziologie a resuscitace, Fakultní nemocnice Brno a Lékařská fakulta, Brno
3 Klinika infekčního lékařství, Fakultní nemocnice Ostrava
4 Katedra interních oborů, Lékařská fakulta, Ostravská univerzita, Ostrava
5 Ústav fyziologie a patofyziologie, Lékařská fakulta, Ostravská univerzita, Ostrava

The alveolo-arterial oxygen difference (P(A-a)O2) describes the difference between alveolar and arterial oxygen tension. The primary purpose of P(A-a)O2 is to distinguish between extra- and intra-pulmonary causes of hypoxemia. P(A-a)O2 has come to the forefront again in the context of the SARS-CoV-2 (COVID-19) coronavirus pandemic, where relatively simple methods of patient triage and therapeutic approaches have been sought. In the intensive care setting, where it is almost always obvious whether the cause of hypoxemia is extrapulmonary or intrapulmonary, the importance of P(A-a)O2 has shifted toward assessing the severity, dynamics, and therapeutic interventions for conditions associated with pulmonary impairment rather than to the initial differentiation between pulmonary and extrapulmonary causes of hypoxemia. This review article aims to present the body of published literature that addresses the use of P(A-a)O2 calculation in the intensive care setting.

Keywords: alveolo-arterial difference, alveolar-arterial gradient, alveolar gas equation, intensive care, ventilation-perfusion impairment, right-to-left shunt.

Received: January 8, 2025; Revised: February 21, 2025; Accepted: March 5, 2025; Prepublished online: March 26, 2025; Published: April 28, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kutěj M, Haiduk F, Sagan J, Máca J. Alveolar-arterial oxygen difference in intensive care. Anest. intenziv. Med. 2025;36(1):22-28. doi: 10.36290/aim.2025.006.
Download citation
PDF will be unlocked 28.4.2026

References

  1. . Sharma S, Hashmi MF, Hendrix JM, Burns B. Alveolar Gas Equation. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 11, 2024.
  2. . Singh A, Soni KD, Singh Y, Aggarwal R, Venkateswaran V, Ashar MS, et al. Alveolar Arterial Gradient and Respiratory Index in Predicting the Outcome of COVID-19 Patients; a Retrospective Cross-Sectional Study. Arch Acad Emerg Med. 2022 Apr 14;10(1):e28. doi: 10.22037/aaem.v10i1.1543. PMID: 35573712; PMCID: PMC9078060. Go to original source... Go to PubMed...
  3. . Hantzidiamantis PJ, Amaro E. Physiology, Alveolar to Arterial Oxygen Gradient. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 5, 2023.
  4. . PubMed® [Internet]. Bethesda: National Library of Medicine; [cited 2024 Jun 05]. Available from: https://pubmed.ncbi.nlm.nih.gov/.
  5. . Vetrugno L, Deana C, Castaldo N, Fantin A, Belletti A, Sozio E, et al; Covimix-Study Group. Barotrauma during Noninvasive Respiratory Support in COVID-19 Pneumonia Outside ICU: The Ancillary COVIMIX-2 Study. J Clin Med. 2023 May 25;12(11):3675. doi: 10.3390/jcm12113675. PMID: 37297869; PMCID: PMC10253529. Go to original source... Go to PubMed...
  6. . Kamran SM, Mirza ZE, Moeed HA, Naseem A, Hussain M, Fazal I Sr, et al. CALL Score and RAS Score as Predictive Models for Coronavirus Disease 2019. Cureus. 2020 Nov 7;12(11):e11368. doi: 10.7759/cureus.11368. PMID: 33304701; PMCID: PMC7721080. Go to original source... Go to PubMed...
  7. . Noureddine S, Roux-Claudé P, Laurent L, Ritter O, Dolla P, Karaer S, et al. Evaluation of long-term sequelae by cardiopulmonary exercise testing 12 months after hospitalization for severe COVID-19. BMC Pulm Med. 2023 Jan 12;23(1):13. doi: 10.1186/s12890-023-02313-x. PMID: 36635717; PMCID: PMC9834678. Go to original source... Go to PubMed...
  8. . Noureddine S, Roux-Claudé P, Laurent L, Ritter O, Dolla P, Karaer S, et al. Evaluation of long-term sequelae by cardiopulmonary exercise testing 12 months after hospitalization for severe COVID-19. BMC Pulm Med. 2023 Jan 12;23(1):13. doi: 10.1186/s12890-023-02313-x. PMID: 36635717; PMCID: PMC9834678. Go to original source... Go to PubMed...
  9. . Wendel Garcia PD, Fumeaux T, Guerci P, Heuberger DM, Montomoli J, Roche-Campo F, et al; RISC-19-ICU Investigators. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine. 2020 Aug;25:100449. doi: 10.1016/j.eclinm.2020.100449. Epub 2020 Jul 6. PMID: 32838231; PMCID: PMC7338015. Go to original source... Go to PubMed...
  10. . Lupieri E, Boffi A, Ltaief Z, Schneider A, Abed-Maillard S, Chiche JD, et al. Response to the first awake prone positioning relates with intubation rate in SARS-CoV-2 patients suffering from acute respiratory failure with moderate to severe hypoxaemia: a retrospective study. Swiss Med Wkly. 2022 Sep 7;152:w30212. doi: 10.4414/smw.2022.w30212. PMID: 36102065. Go to original source... Go to PubMed...
  11. . Raimondi F, Novelli L, Marchesi G, Fabretti F, Grazioli L, Riva I, et al. Worsening of gas exchange parameters at high FiO2 in COVID-19: misleading or informative? Multidiscip Respir Med. 2021 May 25;16(1):759. doi: 10.4081/mrm.2021.759. PMID: 34123380; PMCID: PMC8168493. Go to original source... Go to PubMed...
  12. . Wagner PD, Malhotra A, Prisk GK. Using pulmonary gas exchange to estimate shunt and deadspace in lung disease: theoretical approach and practical basis. J Appl Physiol (1985). 2022;132(4):1104-1113. doi:10.1152/japplphysiol.00621.2021. Go to original source... Go to PubMed...
  13. . Riley RL, Cournand A. Ideal alveolar air and the analysis of ventilation-perfusion relationships in the lungs. J Appl Physiol. 1949;1(12):825-847. doi:10.1152/jappl.1949.1.12.825. Go to original source... Go to PubMed...
  14. . Trapnell BC, Inoue Y, Bonella F, Morgan C, Jouneau S, Bendstrup E, et al; IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med. 2020 Oct 22;383(17):1635-1644. doi: 10.1056/NEJMoa1913590. Epub 2020 Sep 7. PMID: 32897035; PMCID: PMC8083051. Go to original source... Go to PubMed...
  15. . Mariani F, Salvaterra E, Lettieri S, De Silvestri A, Corino A, Bosio M, et al. A mini-whole lung lavage to treat autoimmune pulmonary alveolar proteinosis (PAP). Respir Res. 2022 Mar 17;23(1):60. doi: 10.1186/s12931-022-01982-2. PMID: 35300687; PMCID: PMC8932062. Go to original source... Go to PubMed...
  16. . Bai JW, Huang JN, Shi SY, Ge A, Lu HW, Sun XL, et al. Updated severity and prognosis score of pulmonary alveolar proteinosis: A multi-center cohort study in China. Front Med (Lausanne). 2023 Feb 7;10:1058001. doi: 10.3389/fmed.2023.1058001. PMID: 36824611; PMCID: PMC9941621. Go to original source... Go to PubMed...
  17. . Marconi L, Palla A, Cestelli L, Lazzeretti M, Carrozzi L, Pistolesi M, et al. Should Perfusion Scintigraphy Be Performed to Follow Patients with Acute Pulmonary Embolism? If So, When? J Nucl Med. 2019 Aug;60(8):1134-1139. doi: 10.2967/jnumed.118.222737. Epub 2019 May 23. PMID: 31123098. Go to original source... Go to PubMed...
  18. . Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995;274(23):1852-1857. Go to original source...
  19. . Bansal K, Gore M, Mittal S. Hepatopulmonary Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; December 6, 2022.
  20. . Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med. 2000 Nov 7;133(9):701-6. doi: 10.7326/0003-4819-133-9-200011070-00012. PMID: 11074903. Go to original source... Go to PubMed...
  21. . Groneberg DA, Fischer A. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med. 2001;135(5):380-381. doi:10.7326/0003-4819-135-5-200109040-00017. Go to original source... Go to PubMed...
  22. . Fallon MB. Methylene blue and cirrhosis: pathophysiologic insights, therapeutic dilemmas. Ann Intern Med. 2000;133(9):738-740. doi:10.7326/0003-4819-133-9-200011070-00016. Go to original source... Go to PubMed...
  23. . Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut. 2002 Dec;51(6):853-9. doi: 10.1136/gut.51.6.853. PMID: 12427789; PMCID: PMC1773478. Go to original source... Go to PubMed...
  24. . Fuhrmann V, Madl C, Mueller C, Holzinger U, Kitzberger R, Funk GC, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology. 2006 Jul;131(1):69-75. doi: 10.1053/j.gastro.2006.04.014. PMID: 16831591. Go to original source... Go to PubMed...
  25. . Lin SH, Chen WT, Tsai MH, Liu LT, Kuo WL, Lin YT, et al. A novel prognostic model to predict mortality in patients with acute-on-chronic liver failure in intensive care unit. Intern Emerg Med. 2024 Apr;19(3):721-730. doi: 10.1007/s11739-024-03536-4. Epub 2024 Feb 22. PMID: 38386096. Go to original source... Go to PubMed...
  26. . Bhattacharjee A, Pradhan D, Bhattacharyya P, Dey S, Chhunthang D, Handique A, et al. How Useful is Extravascular Lung Water Measurement in Managing Lung Injury in Intensive Care Unit? Indian J Crit Care Med. 2017 Aug;21(8):494-499. doi: 10.4103/ijccm.IJCCM_40_17. PMID: 28904478; PMCID: PMC5588483. Go to original source... Go to PubMed...
  27. . Bellomo R, Farmer M, Wright C, Parkin G, Boyce N. Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: clinical experience and comparison with conventional dialysis. Blood Purif. 1995;13(5):246-254. doi:10.1159/000170208. Go to original source... Go to PubMed...
  28. . Cancio LC, Galvez E Jr, Turner CE, Kypreos NG, Parker A, Holcomb JB. Base deficit and alveolar-arterial gradient during resuscitation contribute independently but modestly to the prediction of mortality after burn injury. J Burn Care Res. 2006 May-Jun;27(3):289-96; discussion 296-7. doi: 10.1097/01.BCR.0000216457.25875.F4. PMID: 16679895. Go to original source... Go to PubMed...
  29. . Lumb PD. A comparison between 25% albumin and 6% hydroxyethyl starch solutions on lung water accumulation during and immediately after cardiopulmonary bypass. Ann Surg. 1987;206(2):210-213. doi:10.1097/00000658-198708000-00015. Go to original source... Go to PubMed...
  30. . Giffhorn H. Avaliação de uma escala de risco em pacientes submetidos à cirurgia de revascularização do miocárdio: análise de 400 casos [Assessment of a risk scale in patients submitted to coronary artery bypass surgery: analysis of 400 cases]. Rev Bras Ter Intensiva. 2008;20(1):6-17. Go to original source...
  31. . Harmoinen A, Kaukinen L, Porkkala T, Tarkka M, Kaukinen S. Off-pump surgery does not eliminate microalbuminuria or other markers of systemic inflammatory response to coronary artery bypass surgery. Scand Cardiovasc J. 2006;40(2):110-116. doi:10.1080/14017430500401220. Go to original source... Go to PubMed...
  32. . Habes QLM, Kant N, Beunders R, van Groenendael R, Gerretsen J, Kox M, et al. Relationships Between Systemic Inflammation, Intestinal Damage and Postoperative Organ Dysfunction in Adults Undergoing Low-Risk Cardiac Surgery. Heart Lung Circ. 2023 Mar;32(3):395-404. doi: 10.1016/j.hlc.2022.12.006. Epub 2023 Jan 6. PMID: 36621395. Go to original source... Go to PubMed...
  33. . Meininger D, Zwissler B, Byhahn C, Probst M, Westphal K, Bremerich DH. Impact of overweight and pneumoperitoneum on hemodynamics and oxygenation during prolonged laparoscopic surgery. World J Surg. 2006;30(4):520-526. doi:10.1007/s00268-005-0133-7. Go to original source... Go to PubMed...
  34. . Sommers KE, Griffith BP, Hardesty RL, Keenan RJ. Early lung allograft function in twin recipients from the same donor: risk factor analysis. Ann Thorac Surg. 1996;62(3):784-790. doi:10.1016/s0003-4975(96)00371-2. Go to original source... Go to PubMed...
  35. . Kim JJ, Kim EY. Identification of Hemodynamic Risk Factors for Apnea Test Failure During Brain Death Determination. Transplant Proc. 2019;51(6):1655-1660. doi:10.1016/j.transproceed.2019.04.029. Go to original source... Go to PubMed...
  36. . Harpin RP, Baker JP, Downer JP, Whitwell J, Gallacher WN. Correlation of the oxygen cost of breathing and length of weaning from mechanical ventilation. Crit Care Med. 1987;15(9):807-812. doi:10.1097/00003246-198709000-00001. Go to original source... Go to PubMed...
  37. . Al-Saady N, Bennett ED. Decelerating inspiratory flow waveform improves lung mechanics and gas exchange in patients on intermittent positive-pressure ventilation. Intensive Care Med. 1985;11(2):68-75. doi:10.1007/BF00254777. Go to original source... Go to PubMed...
  38. . Chang EM, Bretherick A, Drummond GB, Baillie JK. Predictive validity of a novel non-invasive estimation of effective shunt fraction in critically ill patients [published correction appears in Intensive Care Med Exp. 2020 Jul 10;8(1):30. doi: 10.1186/s40635-020-00320-4]. Intensive Care Med Exp. 2019;7(1):49. Published 2019 Aug 20. doi:10.1186/s40635-019-0262-1. Go to original source... Go to PubMed...
  39. . Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-829. Go to original source...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.